SCHEMBL30296504

SCHEMBL30296504

Nc1cc(Cl)c(F)cc1Oc1ccc2nonc2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2A P28223 5/20 0.35
▸ SLC6A4 P31645 5/20 0.35
▸ KCNH2 Q12809 5/20 0.35
▸ MAPT P10636 3/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ EPAS1 Q99814 1/20 0.35
▸ LMNA P02545 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ SOS1 Q07889 2/20 0.33
▸ RAF1 P04049 1/20 0.33
▸ BRAF P15056 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30296710 0.89 MPO (0.38) MAPTKDM4EMEN1ALDH1A1CYP1A2
SCHEMBL30296282 0.79 MERTK (0.42) MAPTKDM4EMEN1ALDH1A1HPGD
SCHEMBL30296294 0.79 MERTK (0.42) MAPTKDM4EMEN1ALDH1A1HPGD
SCHEMBL26132877 0.74 ARNT (0.39) MAPTKDM4EMEN1HPGDKMT2A
SCHEMBL30296415 0.73 SCN9A (0.36) CYP2D6ENPP2SCN9A
SCHEMBL11016387 0.73 MRGPRX4 (0.44) HTR2ASLC6A4KCNH2MAPTKDM4E
SCHEMBL11014355 0.70 FFAR1 (0.48) HTR2ASLC6A4KCNH2MAPTMEN1
SCHEMBL11010860 0.69 MAPT (0.40) HTR2ASLC6A4KCNH2MAPTKDM4E
SCHEMBL18796168 0.68 PPARG (0.48) MAPTLMNAHTT
SCHEMBL24997038 0.68 ACHE (0.36) HTR2ASLC6A4MAPTKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368173-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2024-11-07 — — US disclosed
EP-4419203-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2024-08-28 — — EP disclosed
CN-118451080-A Tricyclic GPR65 modulators 帕蒂奥斯治疗有限公司 2024-08-06 — — CN disclosed
WO-2023067322-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2023-04-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368173-A1 TRICYCLIC GPR65 MODULATORS GPR65, GPR3, NR1H2 HTR2A 254/4885SLC6A4 1112/4885KCNH2 878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback